Inovio Pharmaceuticals (INO) Stock Research, Analysis & News

Quick Analysis on Inovio Pharmaceuticals (INO) Stock as of May 24, 2017

Previous Closing Price $7.13 is above 50 day moving average of $6.52
Previous Closing Price $7.13 is above 200 day moving average of $6.78
The Stock pays no dividend
The closing price $7.13 is more than 51.47% away from its one year target price of $10.800
Current Short Ratio 14.950 is great than 1
Next year EPS Estimate of $-1.360 is lower than curreny year EPS Estimate $-1.080
Earning per Share $-1.210 is negative. Inovio Pharmaceuticals is lossing money.
EBITDA $-80.30M is negative
(See more information about Inovio Pharmaceuticals (INO) Stock below)

Inovio Pharmaceuticals (INO) Stock Profile Summary

Inovio Pharmaceuticals, Inc. engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. Its SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. The companys proprietary electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The companys clinical programs include trials for human papillomavirus/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus, and human immunodeficiency virus vaccines. It also advances preclinical research for seasonal/pandemic influenza vaccine. Inovio Pharmaceuticals partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. on May 14, 2010. Inovio Pharmaceuticals was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.

Inovio Pharmaceuticals (INO) Stock Key Statistics Research and Analysis as of May 24, 2017

Stock ExchangeNMS
Market Capitalization$667.54M
Trade Volume (Average Trading Volume)4,040,560 (768,206)
Price/Sales14.138
Price/Book5.028
Earning/Share$-1.210
Current Year EPS Estimate$-1.080
Next Year EPS Estimate$-1.360
Previous Closing Price$7.13
50 Day Price Moving Average$6.52
200 Day Price Moving Average$6.78
1 yr Target Price$10.800
PEG Ratio0.000
Short Ratio14.950
EBITDA$-80.30M

Inovio Pharmaceuticals (INO) Stock Competitor Research and Analysis

AstraZeneca PLC (AZN)Pfizer Inc. (PFE)
Sanofi-Aventis (SNY)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Novartis AG (NVS)

Stock Research on Inovio Pharmaceuticals (INO)

Latest Market News on Inovio Pharmaceuticals (INO)


Click here to find the latest news on Inovio Pharmaceuticals (INO)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

AstraZeneca PLC (AZN)
Pfizer Inc. (PFE)
Sanofi-Aventis (SNY)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Novartis AG (NVS)